ABSTRACT
Most cancers, including prostate cancers, express the M2 splice isoform of pyruvate kinase (Pkm2). This isoform can promote anabolic metabolism to support cell proliferation; however, Pkm2 expression is dispensable for many cancers in vivo. Pyruvate kinase M1 (Pkm1) isoform expression is restricted to relatively few tissues and has been reported to promote growth of select tumors, but the role of PKM1 in cancer has been less studied. Pkm1 is expressed in normal prostate tissue; thus, to test how differential pyruvate kinase isoform expression affects cancer initiation and progression we generated mice harboring a conditional allele of Pkm1 and crossed this allele, as well as a Pkm2 conditional allele, to a Pten loss-driven prostate cancer model. We found that Pkm1 loss leads to Pkm2 expression and accelerates prostate cancer, while deletion of Pkm2 leads to increased Pkm1 expression and suppresses cancer. Consistent with these data, a small molecule pyruvate kinase activator that mimics a PKM1-like state suppresses progression of established prostate tumors. PKM2 expression is retained in most human prostate cancers, arguing that pharmacological PKM2 activation may be beneficial for some prostate cancer patients.
Competing Interest Statement
C.J.T. has a patent on TEPP46. M.G.V.H. and L.C.C. have a patent on activation of pyruvate kinase for therapy, and are consultants and advisory board members for Agios Pharmaceuticals. L.C.C. is a founder and advisory board member of Agios Pharmaceuticals, Ravenna Pharmaceuticals, and Faeth Therapeutics. M.G.V.H. is also a consultant and advisory board member for Aeglea Biotherapeutics, iTeos Therapeutics, Faeth Therapeutics, and Auron Therapeutics.
